

Resolutions Adopted at the Extraordinary General Meeting in September 2026

We hereby report that the Extraordinary General Meeting of Shareholders of ONCOMATRYX BIOPHARMA, S.A. was held on first call on September 16, 2026, at 12:00 p.m. at the Company's registered office, located at Bizkaia Technology Park, Building 801b, Derio, Bizkaia, with shareholders attending both in person and remotely. Shareholders representing 93.87% of the voting share capital attended, either in person or by proxy.

All resolutions included on the agenda were unanimously approved, with the following breakdown:

- o In favor: 100%
- o Against: 0%
- o Abstentions: 0%

The resolutions set forth on the agenda were approved, relating to:

- o Reduction of the Company's share capital through the redemption of four hundred sixty-eight thousand five hundred fifty-two (468,552) treasury shares.
- o Appointment, for the term specified in the bylaws, of Fundación Bancaria Kutxa-Kutxa Banku Fundazioa as a member of the Company's board of directors.
- o Setting the maximum number of directors, within the minimum and maximum limits established in the bylaws.
- o Amendment of Article 25 of the Company's bylaws, effective January 1, 2027. Replacement of the CEO's variable compensation.
- o Approval of the CEO's maximum compensation effective January 1, 2027.
- o Determination of the CEO's compensation effective January 1, 2027.
- o Delegation of powers.
- o Drafting, reading, and approval of the minutes of the Shareholders' Meeting.

In Derio, on September 28, 2026.

Mr. Laureano Simón Buela

CEO of Oncomatryx Biopharma, S.A.